[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569912":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":27,"responsibleParty":41,"collaborators":27,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":27,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":27,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":27,"overallStatus":63,"whyStopped":27,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":27},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dachaihu Decoction combined Erzhiwan with variation granules","EXPERIMENTAL","Chinese medicine granules",[13],"Drug: Dachaihu Decoction combined Erzhiwan with variation",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo granules","PLACEBO_COMPARATOR",[18],"Other: Placebo granules",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Dachaihu Decoction combined Erzhiwan with variation",[9],[11],{"type":6,"name":15,"description":15,"armGroupLabels":26,"otherNames":27},[15],null,[29],{"name":30,"affiliation":5,"role":31},"Zhixiu Lin, Prof","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":27,"email":36},"CONTACT","39436347","linzx@cuhk.edu.hk",{"name":38,"role":34,"phone":39,"phoneExt":27,"email":40},"Cho Wing Lo","35053476","louislo@cuhk.edu.hk",{"type":31,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Prof. Lin Zhixiu","Professor","100569912","phase-2-rct-for-the-chinese-medicine-in-treating-hypercholesterolemia-100569912",false,"NCT06700408","RCT for the Chinese Medicine in Treating Hypercholesterolemia","Efficacy and Safety of Dachaihu Decoction Combined Erzhiwan With Variation for the Treatment of Hypercholesterolemia: A Parallel, Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years old, any gender;\n* LDL-C level of 4.1 mmol\u002FL or above (no statin therapy during the screening period);\n* Be able to maintain a more consistent lifestyle and eating habits throughout the study;\n* Have a fixed residence and are not expected to move or travel for 8 weeks;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);\n* Alcohol or drug abuse within the last 3 months;\n* Known liver function or renal dysfunction;\n* History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;\n* Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;\n* Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;\n* Patients with known secondary hypercholesterolemia.","ALL","18 Years","80 Years",{"count":55,"type":56},70,"ESTIMATED","INTERVENTIONAL",[59],"PHASE2","This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.",[62],"Hypercholesterolemia","NOT_YET_RECRUITING","2026-07-28",{"date":66,"type":67},"2026-07-30","ACTUAL",{"date":69,"type":56},"2027-01",{"date":71,"type":56},"2030-04",{"name":5,"class":6}]